Lynparza

ESMO 2019 preview – PARPs on parade
ESMO 2019 preview – PARPs on parade
EP Vantage
ESMO
PARP inhibitors
Lynparza
AstraZeneca
ovarian cancer
GSK
Zejula
Flag link:
AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatment
AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatment
Pharmaforum
AstraZeneca
Merck
Lynparza
clinical trials
advanced ovarian cancer
ovarian cancer
Calquence
Flag link:
AstraZeneca Success On Prostate Cancer Drug Lowers Enthusiasm For Clovis
AstraZeneca Success On Prostate Cancer Drug Lowers Enthusiasm For Clovis
Yahoo/Benzinga
AstraZeneca
Clovis Oncology
prostate cancer
Lynparza
Flag link:
AstraZeneca cancer drugs build as primary care shrinks
AstraZeneca cancer drugs build as primary care shrinks
Biopharma Dive
AstraZeneca
cancer
oncology
primary care
Tagrisso
Symbicort
Lynparza
Flag link:
Clovis investors feel more Lynparza pressure
Clovis investors feel more Lynparza pressure
EP Vantage
prostate cancer
Lynparza
Rubraca
Clovis Oncology
AstraZeneca
Merck
Flag link:
AstraZeneca, Merck herald PhIII prostate cancer win for Lynparza — overtaking Clovis, J&J in PARP race
AstraZeneca, Merck herald PhIII prostate cancer win for Lynparza — overtaking Clovis, J&J in PARP race
Endpoints
Lynparza
AstraZeenca
Merck
prostate cancer
clinical trials
Flag link:
AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment
AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment
Yahoo/Reuters
AstraZeneca
Lynparza
ovarian cancer
Europe
Flag link:
ASCO 2019 day one
ASCO 2019 day one
Pharmaforum
ASCO 2019
JNJ
Erleada
AstraZeneca
Merck
Lynparza
prostate cancer
Flag link:
Lynparza on cusp of EU approval for advanced ovarian cancer
Lynparza on cusp of EU approval for advanced ovarian cancer
Pharmaforum
AstraZeneca
Lynparza
Europe
CHMP
ovarian cancer
Flag link:
AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancer
AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancer
Pharmaforum
AstraZeneca
Merck
Lynparza
BRCA-mutant breast cancer
Europe
breast cancer
Flag link:
Early pancreatic cancer data give Clovis a new path in PARP market
Early pancreatic cancer data give Clovis a new path in PARP market
Biopharma Dive
pancreatic cancer
Clovis Oncology
AstraZeneca
PARP inhibitors
AACR
Rubraca
Lynparza
Flag link:
Myriad Genetics' New FDA Nod for BRACAnalysis CDx Widens Base
Myriad Genetics' New FDA Nod for BRACAnalysis CDx Widens Base
Yahoo/Zacks.com
Myriad Genetics
AstraZeneca
BRACAnalysis CDx
diagnostics
Lynparza
Flag link:
FDA hands AstraZeneca and Merck a snap OK to market Lynparza in frontline ovarian cancer, marking a new standard in treatment
FDA hands AstraZeneca and Merck a snap OK to market Lynparza in frontline ovarian cancer, marking a new standard in treatment
Endpoints
AstraZeneca
Merck
Lynparza
BRCA-mutated ovarian cancer
FDA
Flag link:
FDA Accepts sNDA for Lynparza for Maintenance Therapy in Advanced Ovarian Cancer and Grants Priority Review
FDA Accepts sNDA for Lynparza for Maintenance Therapy in Advanced Ovarian Cancer and Grants Priority Review
CP Wire
Lynparza
Merck
AstraZeneca
ovarian cancer
FDA
Flag link:
FDA Accepts sNDA for Lynparza for Maintenance Therapy in Advanced Ovarian Cancer and Grants Priority Review
Lynparza
Merck
AstraZeneca
ovarian cancer
Flag link:
PARPs may be crushing it in the clinic, but half of doctors are still wary: executive
PARPs may be crushing it in the clinic, but half of doctors are still wary: executive
Fierce Pharma
PARP inhibitors
physicians
Zejula
Rubraca
Lynparza
AstraZeneca
Merck
Tesaro
Clovis Oncology
Flag link:
Mammoth Lynparza survival win puts AZ, Merck in line for $1B launch
Mammoth Lynparza survival win puts AZ, Merck in line for $1B launch
Fierce Pharma
AstraZeneca
Merck
Lynparza
PARP inhibitors
BRCA-mutated ovarian cancer
Flag link:
AstraZeneca, Merck’s Lynparza gets FDA ODD for pancreatic cancer
AstraZeneca, Merck’s Lynparza gets FDA ODD for pancreatic cancer
Pharmaceutical Business Review
AstraZeneca
Merck
Lynparza
FDA
pancreatic cancer
orphan drug
Flag link:
Major Expected Events from AstraZeneca’s R&D in H2 2018
Major Expected Events from AstraZeneca’s R&D in H2 2018
Market Realist
AstraZeneca
China
Lynparza
Tagrisso
Imfinzi
Flag link:
PARP inhibitors show promise for treating ALS and other brain disorders
PARP inhibitors show promise for treating ALS and other brain disorders
Fierce Biotech
PARP inhibitors
AstraZeneca
Lynparza
Tesaro
Zejula
ALS
Flag link:

Pages